Vofatamab Biosimilar – Anti-FGFR3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1548; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Vofatamab biosimilar is a novel monoclonal antibody (mAb) that specifically targets the fibroblast growth factor receptor 3 (FGFR3). It is a research grade antibody that has shown promising results in pre-clinical studies for the treatment of various cancers and other diseases. In this article, we will delve into the structure, activity, and potential applications of this potent antibody.
Vofatamab biosimilar is a fully humanized IgG1 antibody, which means that it is derived from human genetic sequences and has a natural structure similar to the antibodies produced by our immune system. It consists of two heavy chains and two light chains, linked together by disulfide bonds. The variable region of the antibody, responsible for binding to the target molecule, is located at the tips of the heavy and light chains.
The amino acid sequence of vofatamab biosimilar has been carefully designed to have high specificity and affinity for FGFR3. This is achieved by targeting a specific region of the receptor, known as the extracellular domain, which is involved in ligand binding and activation of downstream signaling pathways.
FGFR3 is a cell surface receptor that plays a crucial role in cell proliferation, differentiation, and survival. Aberrant activation of FGFR3 has been linked to the development and progression of various cancers, including bladder, lung, and breast cancer. Vofatamab biosimilar works by binding to FGFR3 and blocking its interaction with ligands, thus inhibiting downstream signaling pathways and halting the growth and survival of cancer cells.
In addition to its anti-tumor activity, vofatamab biosimilar has also shown potential in the treatment of non-cancerous conditions that are caused by dysregulated FGFR3 signaling. For example, it has been found to be effective in treating skeletal dysplasias, a group of genetic disorders characterized by abnormal bone growth due to mutations in FGFR3.
Vofatamab biosimilar is currently being evaluated in pre-clinical and clinical trials for its potential as a therapeutic agent. Its high specificity for FGFR3 makes it a promising candidate for targeted therapy, which aims to selectively kill cancer cells while sparing healthy cells. This can potentially lead to fewer side effects and better treatment outcomes for patients.
Furthermore, vofatamab biosimilar has shown synergistic effects when combined with other anti- cancer agents, such as chemotherapy and other targeted therapies. This highlights its potential for use in combination therapy, which is often more effective than single-agent therapy in treating complex diseases like cancer.
Vofatamab biosimilar is a promising anti-FGFR3 monoclonal antibody that has shown strong potential in pre-clinical studies. Its specific targeting of FGFR3 and its potential for combination therapy make it a valuable candidate for the treatment of various cancers and other diseases. Further research and clinical trials are needed to fully understand its therapeutic potential and bring it to the market as a safe and effective treatment option.
Keywords: Vofatamab biosimilar, monoclonal antibody, FGFR3, targeted therapy, cancer, skeletal dysplasias
ProteoGenix catalogue number PX-TA1548. For research use only.
Target: Vofatamab Biosimilar – Anti-FGFR3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Vofatamab Biosimilar – Anti-FGFR3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
